OBJECTIVE: To evaluate the impact of an intervention addressed to health professionals to improve the adequacy of lipid-lowering prescription in primary prevention of cardiovascular disease and reducing expenditure in this respect. DESIGN: a cluster randomized clinical trial, not blind; Data were obtained from medical records and other primary care databases. SETTING: 279 primary health care teams in Catalonia (Spain), centers managed by Catalan Health Institute (ICS) SUBJECTS: Population from 35 to 74 years, free of cardiovascular disease, who have been started on lipid-lowering therapy during 2 consecutive years of study. INTERVENTION: Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering. This information is updated monthly for 12 consecutive months.Information will be presented in two different and complementary ways to each practitioner: asynchronous information (the patient is not present when the practitioner receives the information) and synchronous information (the patient is present when the practitioner receives the information). VARIABLES: 1. Primary Outcomes are: * Variable RETIRA: new lipid-lowering treatments initiated during the year prior to the intervention, seen as inadequate and withdrawn during the intervention period. * Variable EVITA: New lipid-lowering treatments started during the intervention period and considered as inadequate. 2. Secondary Outcomes are: * Variable COST: total cost of the inadequate new lipid-lowering treatments. * Variable RECORD: recording of the cardiovascular risk. 2.Other variables: * Principal: intervention/control group assignment of health professional. * Patient variables: demographic and clinical. * Professional variables: quality of care indicators. STATISTICAL ANALYSIS: Descriptive analysis, agreggated at health professional level, will be performed and subsequently multilevel analysis techniques will be used to estimate the effect of intervention according to hierarchic data structure and, in particular, patient variables effect.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
60,000
Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering. This information is updated monthly for 12 consecutive months.Information will be presented in two different and complementary ways to each practitioner: asynchronous information (the patient is not present when the practitioner receives the information) and synchronous information (the patient is present when the practitioner receives the information).
IDIAP Jordi Gol
Barcelona, Barcelona, Spain
percentage of participants with increase of the adequacy of lipid-lowering prescription
The primary outcome is the improvement in the appropriateness of prescribing of lipid-lowering therapy in primary prevention as recommended by the guide clinical practice intervention in the Institut Català de la Salut compared with clinical practice group. To answer the main objective of the study, two dependent variables were calculated: * Variable RETIRA: new lipid-lowering treatments initiated during the year prior to the intervention, seen as inadequate and withdrawn during the intervention period * Variable EVITA: New lipid-lowering treatments started during the intervention period and considered as inadequate
Time frame: up to 24 months
percentage of patients with cardiovascular risk register in the clinical records of patients
To assess the degree of cardiovascular risk register in the clinical records of patients RECORD variable is calculated: Variable RECORD: recording of the cardiovascular risk
Time frame: up to 24 months
Change from baseline in the total cost of the lipid-lowering treatments prescribed during the study period
to assess the economic impact of the new primary prevention lipid-lowering treatments prescribed during the study period. To be determined by variable COST Variable COST: total cost of the inadequate new lipid-lowering treatments
Time frame: baseline, months 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.